Amylin receptor: A common pathophysiological target in Alzheimer's disease and diabetes mellitus

31Citations
Citations of this article
87Readers
Mendeley users who have this article in their library.

Abstract

Amylin (islet amyloid polypeptide) and amyloid-beta (Aβ) protein, which are deposited within pancreatic islets of diabetics and brains of Alzheimer's patients respectively, share many biophysical and physiological properties. Emerging evidence indicates that the amylin receptor is a putative target receptor for the actions of human amylin and Aβ in the brain. The amylin receptor consists of the calcitonin receptor dimerized with a receptor activity-modifying protein and is widely distributed within central nervous system. Both amylin and Aβ directly activate this G protein-coupled receptor and trigger multiple common intracellular signal transduction pathways that can culminate in apoptotic cell death. Moreover, amylin receptor antagonists can block both the biological and neurotoxic effects of human amylin and Aβ. Amylin receptors thus appear to be involved in the pathophysiology of Alzheimer's disease and diabetes, and could serve as a molecular link between the two conditions that are associated epidemiologically. © 2013 Fu, Patel and Jhamandas.

Cite

CITATION STYLE

APA

Fu, W., Patel, A., & Jhamandas, J. H. (2013). Amylin receptor: A common pathophysiological target in Alzheimer’s disease and diabetes mellitus. Frontiers in Aging Neuroscience, 5(AUG). https://doi.org/10.3389/fnagi.2013.00042

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free